Theranostics: New Era in Nuclear Medicine and Radiopharmaceuticals

Author:

Deep Kaur Chanchal,Kumar Mishra Koushlesh,Sahu Anil,Panik Rajnikant,Kashyap Pankaj,Prasad Mishra Saraswati,Kumar Anand

Abstract

Malignancy and many inflammatory diseases have become a major concern for mankind over the years. The conventional therapy of these diseases lacks the effectiveness of the better diagnosis and targeted treatment of these diseases, but nuclear medicine can be regarded as a savior in the current scenario. Over the years, radioactivity of radioisotopes has been employed for treatment of many diseases. Nuclear medicines came up with radiopharmaceuticals that impart the ability to destroy specific diseased cells with high-energy-emitting radionuclides. Moreover, the emergence of theranostics, which is a combination of single drug used both for diagnostic as well as therapeutic purpose, has added a new feather in the field of nuclear medicines for providing a specific and personalized treatment to the patient. The current chapter discusses about techniques used for imaging of these radionuclides for better therapy and diagnosis of the root cause of the concerned disease by positron emission tomography (PET)/CT and single photon emission computed tomography (SPECT)/CT as well as the advantages and disadvantages associated with them. It also describes about applications of theranostics and nuclear imaging in cancer treatment and their future perspective.

Publisher

IntechOpen

Reference33 articles.

1. The Medicines Act 1968 (Application to Radiopharmaceutical-associated Products) Regulations. London: HMSO; 1992. Available from: www.legislation.gov.uk/uksi/1992/605/contents/made [Accessed: 03 June 2011]

2. Theobald T. Sampson’s Textbook of Radiopharmacy. 4th ed. London: Pharmaceutical Press; 2011

3. Administration of Radioactive Substances Advisory Committee. Notes for Guidance on the Clinical Administration of Radiopharmaceuticals and Use of Sealed Radioactive Sources. 2006. Available from: www.arsac.org.uk/notes_for_guidance [Accessed: 03 June 2011]

4. International Commission on Radiological Protection. Radiation dose to the patient from radiopharmaceuticals. Annals of the ICRP. 1988;18:1-4

5. Chowdhury FU, Scarsbrook AF. The role of hybrid SPECT-CT in oncology: Current and emerging clinical applications. Clinical Radiology. 2008;63(3):241-251

Cited by 3 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3